Investigational drug · Phase 3
Sasanlimab
Also called: PF-06801591
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-muscle Invasive Bladder Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
23
Any phase or sponsor naming "Sasanlimab"
First trial start
2019
Dec 30, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sasanlimab", any sponsor or status.
- Phase 117
Conditions studied
As listed on its trial records.
- Non-muscle Invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Sasanlimab" as an intervention, largest first.
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT04165317 · 1,068 participants · Start Dec 30, 2019 · Primary completion Dec 2, 2024
Drug: PF-06801591; Bacillus Calmette-Guerin · For: Non-muscle Invasive Bladder Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; La Jolla, California · 195 sites in all
PfizerPfizer (PFE)
NCT07206225 · 294 participants (planned) · Start Nov 6, 2025 · Primary completion Jan 29, 2030
Drug: PF-08052667; Sasanlimab and 2 more · For: Non-muscle Invasive Bladder Cancer
Sites: Birmingham, Alabama; Ruskin, Florida; Tampa, Florida · 69 sites in all
- Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04181788 · 155 participants · Start Mar 18, 2020 · Primary completion Mar 3, 2022
Drug: PF-06801591 · For: Advanced Malignancies; Non-small-cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Nanjing, China · 49 sites in all
Seagen Inc.Pfizer (PFE)
NCT04254107 · 133 participants · Start May 29, 2020 · Primary completion Dec 1, 2023
Drug: SEA-TGT; sasanlimab and 1 more · For: Non-small Cell Lung Cancer; Gastric Carcinoma; Gastroesophageal Junction Carcinoma and 9 more
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 36 sites in all
National Cancer Institute (NCI)NIH
NCT05665361 · 100 participants (planned) · Start Apr 24, 2024 · Primary completion Jun 1, 2027
Drug: Sasanlimab; Palbocicilib · For: Advanced Clear Cell Renal Carcinoma (Ccrcc); Papillary Renal Cell Carcinoma (Prcc)
Sites: Bethesda, Maryland
PfizerPfizer (PFE)
NCT04458259 · 88 participants · Start Sep 24, 2020 · Primary completion Nov 15, 2024
Drug: PF-07265807; Sasanlimab and 1 more · For: Neoplasm Metastasis
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 33 sites in all
- Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer PatientsNot yet recruiting
Fundación de investigación HMAcademic, hospital or other
NCT06623162 · 70 participants (planned) · Start Dec 2024 · Primary completion Dec 2026
Drug: gemcitabine + cisplatine · For: Mibc; Muscle Invasive Bladder Cancer
Sites: Madrid, Spain
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Active, not recruiting
PfizerPfizer (PFE)
NCT06447662 · 64 participants · Start Jun 27, 2024 · Primary completion Oct 9, 2026
Drug: PF-07934040 · For: Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 27 sites in all
PfizerPfizer (PFE)
NCT04585815 · 34 participants · Start Nov 10, 2020 · Primary completion May 17, 2023
Drug: Sasanlimab Prefilled syringe; Encorafenib and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Duarte, California; Encinitas, California; Fresno, California · 55 sites in all
- Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder CancerActive, not recruiting
The Methodist Hospital Research InstituteAcademic, hospital or other
NCT05241340 · 33 participants (planned) · Start Feb 15, 2022 · Primary completion Aug 1, 2025
Drug: Sasanlimab · For: Urothelial Carcinoma Bladder
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.
Fakih M, Doi T, Tolcher A, et al. · Cancer Res Commun 2026
- [Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].
Gakis G, Vom Dorp F · Urologie 2026
- Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.
Masters JC, Jermain B, Liu A, et al. · J Clin Pharmacol 2026
- Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer.
McGrath J, Banerjee I, Ishiyama Y, et al. · Urol Oncol 2026
- Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
Joyce DD, Sharma V, Ratcliff GE, et al. · J Urol 2026
- Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.
Develtere D, Tsantoulis P, Olivier T · Eur J Cancer 2026
Also in development for Non-muscle Invasive Bladder Cancer
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- TARA-002Phase 33 trials
Protara Therapeutics · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- EG-70Phase 21 trial
enGene, Inc. · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.